4//SEC Filing
Fenimore Christopher R. 4
Accession 0001968202-24-000061
CIK 0000872589other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:02 PM ET
Size
18.1 KB
Accession
0001968202-24-000061
Insider Transaction Report
Form 4
Fenimore Christopher R.
VP, Controller
Transactions
- Sale
Common Stock
2024-02-09$954.57/sh−1,100$1,050,027→ 14,972 total - Sale
Common Stock
2024-02-09$950.49/sh−344$326,969→ 18,947 total - Sale
Common Stock
2024-02-09$951.39/sh−487$463,327→ 18,460 total - Sale
Common Stock
2024-02-09$952.62/sh−1,046$996,441→ 17,414 total - Sale
Common Stock
2024-02-09$953.47/sh−1,342$1,279,557→ 16,072 total - Sale
Common Stock
2024-02-09$955.00/sh−600$573,000→ 14,372 total
Holdings
- 4,269(indirect: 2022 GRAT)
Common Stock
- 1,897(indirect: By Trust)
Common Stock
- 460(indirect: By Trust)
Common Stock
- 1,473(indirect: 2021 GRAT)
Common Stock
- 1,499(indirect: By 401(k))
Common Stock
- 461(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]Represents volume-weighted average price of sales of 344 shares of Company stock on February 9, 2024 at prices ranging from $950.33 to $950.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
- [F2]Represents volume-weighted average price of sales of 487 shares of Company stock on February 9, 2024 at prices ranging from $951.03 to $951.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
- [F3]Represents volume-weighted average price of sales of 1,046 shares of Company stock on February 9, 2024 at prices ranging from $952.11 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
- [F4]Represents volume-weighted average price of sales of 1,342 shares of Company stock on February 9, 2024 at prices ranging from $953.02 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
- [F5]Represents volume-weighted average price of sales of 1,100 shares of Company stock on February 9, 2024 at prices ranging from $954.00 to $954.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
- [F6]These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
Documents
Issuer
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Entity typeother
Related Parties
1- filerCIK 0001697422
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:02 PM ET
- Size
- 18.1 KB